JP2016529312A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529312A5
JP2016529312A5 JP2016540387A JP2016540387A JP2016529312A5 JP 2016529312 A5 JP2016529312 A5 JP 2016529312A5 JP 2016540387 A JP2016540387 A JP 2016540387A JP 2016540387 A JP2016540387 A JP 2016540387A JP 2016529312 A5 JP2016529312 A5 JP 2016529312A5
Authority
JP
Japan
Prior art keywords
alkyl
carbocyclyl
heterocyclyl
alkynyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016540387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529312A (ja
JP6336598B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/054114 external-priority patent/WO2015035062A1/en
Publication of JP2016529312A publication Critical patent/JP2016529312A/ja
Publication of JP2016529312A5 publication Critical patent/JP2016529312A5/ja
Application granted granted Critical
Publication of JP6336598B2 publication Critical patent/JP6336598B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016540387A 2013-09-05 2014-09-04 抗増殖性化合物 Expired - Fee Related JP6336598B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874310P 2013-09-05 2013-09-05
US61/874,310 2013-09-05
PCT/US2014/054114 WO2015035062A1 (en) 2013-09-05 2014-09-04 Antiproliferative compounds

Publications (3)

Publication Number Publication Date
JP2016529312A JP2016529312A (ja) 2016-09-23
JP2016529312A5 true JP2016529312A5 (https=) 2017-09-07
JP6336598B2 JP6336598B2 (ja) 2018-06-06

Family

ID=51541384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540387A Expired - Fee Related JP6336598B2 (ja) 2013-09-05 2014-09-04 抗増殖性化合物

Country Status (9)

Country Link
US (1) US9505767B2 (https=)
EP (1) EP3041474B1 (https=)
JP (1) JP6336598B2 (https=)
KR (1) KR20160049003A (https=)
CN (1) CN105611933B (https=)
CA (1) CA2922925A1 (https=)
MX (1) MX2016002794A (https=)
RU (1) RU2016112568A (https=)
WO (1) WO2015035062A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2903968T3 (en) 2012-10-02 2017-01-30 Gilead Sciences Inc INHIBITORS OF HISTON DEMETHYLASES
PE20151667A1 (es) 2013-02-27 2015-11-27 Epitherapeutics Aps Inhibidores de histona desmetilasas
KR20150130491A (ko) * 2013-03-13 2015-11-23 제넨테크, 인크. 피라졸로 화합물 및 그것의 용도
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
RU2684396C2 (ru) 2014-10-29 2019-04-09 Донг-А Ст Ко., Лтд. Новые соединения пиридопиримидинона для модулирования каталитической активности гистонлизиндеметилаз (KDMS)
EP3294313A4 (en) * 2015-05-15 2019-04-17 The General Hospital Corporation METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE
JP6832430B2 (ja) 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ, インコーポレイテッド 細胞代謝過程の阻害剤
EP3525786A4 (en) * 2016-10-12 2020-03-18 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
EP3525785B1 (en) * 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
US11124795B2 (en) 2017-02-28 2021-09-21 University Of Massachusetts Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
CN108947985A (zh) * 2017-05-22 2018-12-07 苏州偶领生物医药有限公司 用作自噬调节剂的化合物及其制备方法和用途
JP2020531519A (ja) 2017-08-21 2020-11-05 ナビゲン,インコーポレーテッド Arf6阻害剤及び関連する方法
SG11202002218VA (en) * 2017-09-15 2020-04-29 Aduro Biotech Inc Pyrazolopyrimidinone compounds and uses thereof
AU2020307544A1 (en) * 2019-06-24 2021-11-18 Dana-Farber Cancer Institute, Inc. E3 ligase binders and uses thereof
EP3999183A4 (en) * 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
CN114728167B (zh) 2019-11-25 2024-03-19 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
WO2023134692A1 (zh) * 2022-01-13 2023-07-20 浙江同源康医药股份有限公司 多环类化合物及其用途
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2025194015A1 (en) * 2024-03-15 2025-09-18 Dem Biopharma, Inc. Heteroaryl modulators of gpr84 and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1996003397A1 (en) 1994-07-21 1996-02-08 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050038A1 (en) 1997-05-06 1998-11-12 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
BR9814116A (pt) 1997-11-06 2000-10-03 American Cyanamid Co Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
JP4100865B2 (ja) * 1999-12-13 2008-06-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 三環式縮合異項環化合物、その製造法およびその医薬
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EP2069351B1 (en) * 2006-06-20 2015-10-28 AbbVie Inc. Pyrazoloquinazolinones as parp inhibitors
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
CN101906105B (zh) 2009-06-08 2013-01-16 河北医科大学 吡唑并[1,5-a]嘧啶酮衍生物及其药物组合物以及其用途
US10953012B2 (en) 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
ES2635016T3 (es) * 2013-03-01 2017-10-02 Fundación Para La Investigación Médica Aplicada Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas
KR20150130491A (ko) 2013-03-13 2015-11-23 제넨테크, 인크. 피라졸로 화합물 및 그것의 용도

Similar Documents

Publication Publication Date Title
JP2016529312A5 (https=)
RU2016112568A (ru) Антипролиферативные соединения
JP2017530984A5 (https=)
JP2018505169A5 (https=)
ES2694513T3 (es) Derivado de quinolina
IL275333B2 (en) Inhibitors of fibroblast activation protein
JP2018510851A5 (https=)
TWI690525B (zh) 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
JP2017528475A5 (https=)
RU2018103944A (ru) Производные этинила как модуляторы метаботропного рецептора глутамата
JP2018520195A5 (https=)
JP2010522194A5 (https=)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2016504365A5 (https=)
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
RU2016130932A (ru) Производные хинолона как ингибиторы рецептора фактора роста фибробластов
RU2015116749A (ru) Антагонисты mglu2/3 для лечения аутических расстройств
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
RU2013147823A (ru) (альфа-замещенные аралкиламино-и гетероарилалкиламино)пиримидинил-и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний
KR20150081344A (ko) 조합 요법
EP3053578B1 (en) Combination cancer therapy using azabicyclo compound
JP2010523700A5 (https=)
RU2016138676A (ru) Ингибиторы усилителя zeste гомолога 2
JP2018507191A5 (https=)